NR3C1 and prostate cancer: Multiple mechanisms of docetaxel resistance exist in prostate cancer, including ABC transporters [23, 24], glucocorticoid receptor (GR) [25], androgen receptor (AR) splicing [26, 27], epithelial plasticity [28, 29], and stem cells [30].